Gut-Derived GLP-1 Released by Rare Sugar d -Allulose Cooperates With Insulin to Activate Left-Sided Vagal Afferents and Enhance Insulin Sensitivity
Diabetes · 2026
DOI: 10.2337/db25-1134 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, 2026. Verfasst von Kento Ohbayashi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Animal Functional Science, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Kyoto, Japan. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Vagus Nerve, Insulin, Insulin Resistance. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Sinai Health-Novo Nordisk Foundation Chair in Regulatory Peptides, Kyoto-based innovative medical technology research and development grant program from the Kyoto Lifetech Innovation Support Center (KLISC), the Adaptable and Seamless Technology transfer Program through Target-driven R&D (A-STEP).
Abstract (Originalsprache)
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) ameliorate hyperglycemia by directly stimulating insulin secretion from the pancreas. In contrast, the physiological role of short-lived endogenous GLP-1 remains unclear largely because of its limited access to pancreatic β-cells. Here, we used d-allulose, a nonmetabolizable noncaloric rare sugar, as a GLP-1 secretagogue. We show that d-allulose–induced intestinal GLP-1 secretion (AIGS) cooperates with insulin to reduce blood glucose levels by enhancing insulin action, rather than insulin secretion, in male mice. This cooperation and remote signaling require left-sided vagal afferents forming the common hepatic branch, but not right-sided afferents. AIGS-enhanced insulin action required both GLP-1Rs and insulin receptor substrate 2 in these neurons. Remarkably, in db/db mice exhibiting severe insulin resistance, AIGS improved insulin resistance and hyperglycemia more rapidly and potently than the GLP-1RA exendin-4. These findings reveal that a subclass of vagal afferent neurons synergistically activated by endogenous intestinal GLP-1 and insulin does not stimulate insulin secretion but augments insulin action to improve glucose tolerance. This novel extrapancreatic GLP-1 action mediated by vagal afferents provides a promising basis for innovative type 2 diabetes therapies. Article Highlights Compared with glucagon-like peptide 1 (GLP-1) receptor agonists, the physiological roles and mechanisms of endogenous, short-lived GLP-1 in glucose metabolism remain poorly understood. We used the rare sugar d-allulose, a noncaloric GLP-1 secretagogue, as a tool to elucidate the physiological actions of endogenous GLP-1. d-Allulose–induced intestinal GLP-1 release cooperates with insulin to activate left-side vagal afferents, enhancing insulin action rather than insulin secretion and thereby regulating glycemic control. Because this acute mechanism improved hyperglycemia in type 2 diabetes to an extent comparable to that observed with GLP-1 receptor agonists, targeting GLP-1/insulin-vagal signaling may inform novel therapies and dietary or nutritional interventions for type 2 diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory of Animal Functional Science, Graduate School of Life and Environmental Sciences, Kyoto Prefectural University, Kyoto, Japan.
- Department of Physiology II, Kanazawa Medical University, Ishikawa, Japan.
- Department of Physiology, School of Medical Sciences, University of Fukui, Fukui, Japan.
- Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
- Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
- Center for Integrative Physiology, Kansai Electric Power Medical Research Institute, Osaka, Japan.
ORCID-Profile: Kento Ohbayashi, Naoto Kubota, Daniel J Drucker, Yusaku Iwasaki
Förderung
- Sinai Health-Novo Nordisk Foundation Chair in Regulatory Peptides
- Kyoto-based innovative medical technology research and development grant program from the Kyoto Lifetech Innovation Support Center (KLISC)
- the Adaptable and Seamless Technology transfer Program through Target-driven R&D (A-STEP)
- Diabetes Canada-Canadian Cancer Society Grant
- an Inamori research grant from the Inamori Foundation
- the Grant-in-Aid for Core Research for Evolutional Science and Technology (CREST)
- Canadian Institutes of Health Research (CIHR) Grants
- the Japan Agency for Medical Research and Development (AMED)
Zitieren
APA
Ohbayashi, K., Tanida, M., Abe, C., Ishihara, H., Omi, W., Kubota, N., Drucker, D. J., Yada, T., & Iwasaki, Y. (2026). Gut-Derived GLP-1 Released by Rare Sugar d -Allulose Cooperates With Insulin to Activate Left-Sided Vagal Afferents and Enhance Insulin Sensitivity. Diabetes. https://doi.org/10.2337/db25-1134
Vancouver
Ohbayashi K, Tanida M, Abe C, Ishihara H, Omi W, Kubota N, et al. Gut-Derived GLP-1 Released by Rare Sugar d -Allulose Cooperates With Insulin to Activate Left-Sided Vagal Afferents and Enhance Insulin Sensitivity. Diabetes. 2026. doi:10.2337/db25-1134
BibTeX
@article{Ohbayashi2026,
author = {Ohbayashi, Kento and Tanida, Mamoru and Abe, Chikara and Ishihara, Hirotaka and Omi, Wataru and Kubota, Naoto and Drucker, Daniel J and Yada, Toshihiko and Iwasaki, Yusaku},
title = {Gut-Derived GLP-1 Released by Rare Sugar d -Allulose Cooperates With Insulin to Activate Left-Sided Vagal Afferents and Enhance Insulin Sensitivity},
journal = {Diabetes},
year = {2026},
doi = {10.2337/db25-1134}
}
EUVIMED